Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

por Yamamoto, Nobuyuki, Mera, Takeshi, Märten, Angela, Hochmair, Maximilian J.
Publicado 2019

Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: report on several cases and review of the literature [ISRCTN62866...

por Hoffmann, Katrin, Marten, Angela, Lindel, Katja, Fritz, Stefan, Jager, Dirk, Buchler, Markus W, Schmidt, Jan
Publicado 2006

Novel non-viral method for transfection of primary leukemia cells and cell lines

por Schakowski, Frank, Buttgereit, Peter, Mazur, Martin, Märten, Angela, Schöttker, Björn, Gorschlüter, Marcus, Schmidt-Wolf, Ingo GH
Publicado 2004

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

por Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Park, Keunchil, Passaro, Antonio, De Marinis, Filippo, Solca, Flavio, Märten, Angela, Kim, Edward S.
Publicado 2022

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving...

por Märten, Angela, Wente, Moritz N, Ose, Jennifer, Büchler, Markus W, Rötzer, Ingeborg, Decker-Baumann, Christiane, Karapanagiotou-Schenkel, Irini, Harig, Sabine, Schmidt, Jan, Jäger, Dirk
Publicado 2009

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients...

por Hoffknecht, Petra, Tufman, Amanda, Wehler, Thomas, Pelzer, Theo, Wiewrodt, Rainer, Schütz, Martin, Serke, Monika, Stöhlmacher-Williams, Jan, Märten, Angela, Maria Huber, Rudolf, Dickgreber, Nicolas J.
Publicado 2015

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mut...

por Park, Keunchil, Kim, Jin-Soo, Kim, Joo-Hang, Kim, Young-Chul, Kim, Hoon-Gu, Cho, Eun Kyung, Jin, Jong-Youl, Kim, Miyoung, Märten, Angela, Kang, Jin-Hyoung
Publicado 2021

Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma

por Märten, Angela, Sievers, Elisabeth, Albers, Peter, Müller, Stefan, Franchy, Christian, von Ruecker, Alexander, Strunk, Holger, Schild, Hans Heinz, Schmiedel, Alexandra, Sommer, Thorsten, Sauerbruch, Tilman, Schmidt-Wolf, Ingo G.H.
Publicado 2006

A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment an...

por Märten, Angela, Schmidt, Jan, Ose, Jennifer, Harig, Sabine, Abel, Ulrich, Münter, Marc W, Jäger, Dirk, Friess, Helmut, Mayerle, Julia, Adler, Guido, Seufferlein, Thomas, Gress, Thomas, Schmid, Roland, Büchler, Markus W
Publicado 2009

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-L...

por Wu, Yi-Long, Xu, Chong-Rui, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Shi, Jian Hua, Märten, Angela, Fan, Jean, Peil, Barbara, Zhou, Caicun
Publicado 2018

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional...

por Miura, Satoru, Jung, Hyun Ae, Lee, Shin Yup, Lee, Seung Hyeun, Lee, Min Ki, Lee, Yong Chul, Hochmair, Maximilian J, Yang, Cheng-Ta, Märten, Angela, Yang, James Chih-Hsin, Popat, Sanjay
Publicado 2022

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Co...

por Wu, Yi-Long, Hirsh, Vera, Sequist, Lecia V., Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Schuler, Martin, Mok, Tony, Yamamoto, Nobuyuki, O’Byrne, Kenneth, Geater, Sarayut L., Zhou, Caicun, Massey, Dan, Märten, Angela, Lungershausen, Juliane, Yang, James Chih-Hsin
Publicado 2017

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

por Popat, Sanjay, Hsia, Te-Chun, Hung, Jen-Yu, Jung, Hyun Ae, Shih, Jin-Yuan, Park, Cheol Kyu, Lee, Seung Hyeun, Okamoto, Tatsuro, Ahn, Hee Kyung, Lee, Yong Chul, Sato, Yuki, Lee, Sung Sook, Mascaux, Celine, Daoud, Hasan, Märten, Angela, Miura, Satoru
Publicado 2022

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

por Ormanns, Steffen, Siveke, Jens T, Heinemann, Volker, Haas, Michael, Sipos, Bence, Schlitter, Anna Melissa, Esposito, Irene, Jung, Andreas, Laubender, Rüdiger P, Kruger, Stephan, Vehling-Kaiser, Ursula, Winkelmann, Cornelia, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Gauler, Thomas C, Märten, Angela, Geissler, Michael, Greten, Tim F, Kirchner, Thomas, Boeck, Stefan
Publicado 2014

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for pat...

por Schuler, Martin, Tan, Eng-Huat, O’Byrne, Kenneth, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Massey, Dan, Märten, Angela, Paz-Ares, Luis, Park, Keunchil
Publicado 2019